MA27887A1 - Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine - Google Patents
Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocineInfo
- Publication number
- MA27887A1 MA27887A1 MA28677A MA28677A MA27887A1 MA 27887 A1 MA27887 A1 MA 27887A1 MA 28677 A MA28677 A MA 28677A MA 28677 A MA28677 A MA 28677A MA 27887 A1 MA27887 A1 MA 27887A1
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- dicetopiperazines
- ocytocin
- antagonists
- indanyl
- Prior art date
Links
- 102400000050 Oxytocin Human genes 0.000 title 1
- 101800000989 Oxytocin Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- -1 2-indanyl Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000003336 oxytocin antagonist Substances 0.000 abstract 1
- 229940121361 oxytocin antagonists Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Dicétopipérazines substituées et leur utilisation comme antagonistes d'ocytocine Composés de formule (1) dans laquelle R1 représente un groupe 2-indanyle, R2 représente un groupe 1-méthylpropyle, R3 représente un groupe 2-méthyl-1,3-oxazole-4-yle et R4 et R5, conjointement avec l'atome d'azote auquel ils sont fixés, représentent un groupe morpholino, un procédé pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en médecine.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314738A GB0314738D0 (en) | 2003-06-24 | 2003-06-24 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27887A1 true MA27887A1 (fr) | 2006-05-02 |
Family
ID=27637257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28677A MA27887A1 (fr) | 2003-06-24 | 2005-12-21 | Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US8071594B2 (fr) |
| EP (1) | EP1641787B1 (fr) |
| JP (1) | JP5128126B2 (fr) |
| KR (1) | KR101131378B1 (fr) |
| CN (2) | CN100404532C (fr) |
| AR (1) | AR044869A1 (fr) |
| AT (1) | ATE361295T1 (fr) |
| AU (1) | AU2004251868B2 (fr) |
| BR (1) | BRPI0411729A (fr) |
| CA (1) | CA2530310C (fr) |
| CY (1) | CY1107703T1 (fr) |
| DE (1) | DE602004006268T2 (fr) |
| DK (1) | DK1641787T3 (fr) |
| EG (1) | EG24929A (fr) |
| ES (1) | ES2285474T3 (fr) |
| GB (1) | GB0314738D0 (fr) |
| HR (1) | HRP20070286T3 (fr) |
| IL (1) | IL172529A (fr) |
| IS (1) | IS2463B (fr) |
| MA (1) | MA27887A1 (fr) |
| MX (1) | MXPA05014068A (fr) |
| MY (1) | MY140653A (fr) |
| NO (1) | NO332677B1 (fr) |
| NZ (1) | NZ544006A (fr) |
| PL (1) | PL1641787T3 (fr) |
| PT (1) | PT1641787E (fr) |
| RU (1) | RU2343152C2 (fr) |
| TW (1) | TWI340745B (fr) |
| WO (1) | WO2005000840A1 (fr) |
| ZA (1) | ZA200509890B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0414100D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| US8716286B2 (en) | 2009-10-30 | 2014-05-06 | Glaxo Group Limited | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione |
| AU2014397706A1 (en) | 2014-06-16 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Retosiban for the treatment of pre-term labour |
| ES2915948T3 (es) | 2016-01-04 | 2022-06-27 | ObsEva SA | Administración conjunta de alfa-aminoéster de derivado de hidroxipropiltiazolidin-carboxamida y un agente tocolítico |
| WO2018015497A2 (fr) | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches |
| CN106674031A (zh) * | 2016-11-18 | 2017-05-17 | 浙江工业大学 | R‑2‑二氢茚氨酸的制备方法 |
| EP4025207A1 (fr) | 2019-09-03 | 2022-07-13 | ObsEva S.A. | Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches |
| AU2021218895A1 (en) | 2020-02-10 | 2022-09-15 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596819A (en) * | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
| US5091387A (en) * | 1990-03-02 | 1992-02-25 | Merck & Co., Inc. | Spirocyclic oxytocin antagonists |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5817751A (en) * | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
| US5968938A (en) * | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
| GB2326639A (en) * | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
| DE69934093T2 (de) | 1998-01-27 | 2007-06-21 | Aventis Pharmaceuticals Inc. | SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER |
| CN1173946C (zh) | 1998-01-29 | 2004-11-03 | 阿温蒂斯药物公司 | 制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法 |
| WO1999047549A1 (fr) | 1998-03-16 | 1999-09-23 | Ontogen Corporation | Piperazines utilisees en tant qu'inhibiteurs de fructose-1,6-bisphosphatase (fbpase) |
| GB2372740A (en) | 2001-01-17 | 2002-09-04 | Xenova Ltd | Diketopiperazines |
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| US20030229001A1 (en) | 2002-01-31 | 2003-12-11 | Pfizer Inc. | Treatment of male sexual dysfunction |
| GB0314738D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0314733D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| GB0414100D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414092D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| CN103930132A (zh) | 2011-09-27 | 2014-07-16 | 拜奥迈德瓦利探索有限公司 | 治疗胶质瘤的组合物和方法 |
-
2003
- 2003-06-24 GB GB0314738A patent/GB0314738D0/en not_active Ceased
-
2004
- 2004-06-22 EP EP04740230A patent/EP1641787B1/fr not_active Expired - Lifetime
- 2004-06-22 WO PCT/EP2004/006814 patent/WO2005000840A1/fr not_active Ceased
- 2004-06-22 RU RU2006101859A patent/RU2343152C2/ru not_active IP Right Cessation
- 2004-06-22 CA CA 2530310 patent/CA2530310C/fr not_active Expired - Fee Related
- 2004-06-22 CN CNB2004800178348A patent/CN100404532C/zh not_active Expired - Fee Related
- 2004-06-22 DK DK04740230T patent/DK1641787T3/da active
- 2004-06-22 KR KR1020057024715A patent/KR101131378B1/ko not_active Expired - Fee Related
- 2004-06-22 ES ES04740230T patent/ES2285474T3/es not_active Expired - Lifetime
- 2004-06-22 NZ NZ544006A patent/NZ544006A/en not_active IP Right Cessation
- 2004-06-22 MY MYPI20042430 patent/MY140653A/en unknown
- 2004-06-22 AU AU2004251868A patent/AU2004251868B2/en not_active Ceased
- 2004-06-22 AT AT04740230T patent/ATE361295T1/de active
- 2004-06-22 CN CNA2008101088194A patent/CN101597282A/zh active Pending
- 2004-06-22 DE DE200460006268 patent/DE602004006268T2/de not_active Expired - Lifetime
- 2004-06-22 PT PT04740230T patent/PT1641787E/pt unknown
- 2004-06-22 BR BRPI0411729 patent/BRPI0411729A/pt not_active Application Discontinuation
- 2004-06-22 JP JP2006516041A patent/JP5128126B2/ja not_active Expired - Fee Related
- 2004-06-22 MX MXPA05014068A patent/MXPA05014068A/es active IP Right Grant
- 2004-06-22 AR ARP040102182 patent/AR044869A1/es not_active Application Discontinuation
- 2004-06-22 HR HR20070286T patent/HRP20070286T3/xx unknown
- 2004-06-22 US US10/561,498 patent/US8071594B2/en not_active Expired - Fee Related
- 2004-06-22 PL PL04740230T patent/PL1641787T3/pl unknown
- 2004-06-23 TW TW093118010A patent/TWI340745B/zh not_active IP Right Cessation
-
2005
- 2005-12-06 ZA ZA200509890A patent/ZA200509890B/en unknown
- 2005-12-12 IL IL172529A patent/IL172529A/en active IP Right Grant
- 2005-12-21 EG EGNA2005000854 patent/EG24929A/xx active
- 2005-12-21 MA MA28677A patent/MA27887A1/fr unknown
-
2006
- 2006-01-20 IS IS8248A patent/IS2463B/is unknown
- 2006-01-24 NO NO20060383A patent/NO332677B1/no not_active IP Right Cessation
-
2007
- 2007-07-24 CY CY071100990T patent/CY1107703T1/el unknown
-
2011
- 2011-09-13 US US13/231,211 patent/US8357685B2/en not_active Expired - Fee Related
-
2012
- 2012-12-14 US US13/715,433 patent/US20130102783A1/en not_active Abandoned
-
2013
- 2013-11-05 US US14/072,376 patent/US8937179B2/en not_active Expired - Fee Related
-
2014
- 2014-12-15 US US14/570,812 patent/US20150105387A1/en not_active Abandoned
-
2015
- 2015-11-20 US US14/946,920 patent/US9452169B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| MA27754A1 (fr) | Pyrimidinones substituees | |
| MA26877A1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
| TNSN05165A1 (fr) | Derives de pyrrolopyrimidine | |
| MA26727A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant | |
| MA26879A1 (fr) | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation. | |
| CA2310141A1 (fr) | Utilisation de derives de benzhydryl sulfinyle pour traiter la somnolence d'origine medicamenteuse | |
| MA29429B1 (fr) | Composes d'arylamine substitues et leur utilisation comme modulateurs de 5-ht6 | |
| HUP0401889A2 (hu) | 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
| YU31303A (sh) | Jedinjenja imidazola sa pripojenim arilom ili heteroarilom kao anti-inflamatorni i analgetički agensi | |
| MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| YU59602A (sh) | Aril fuzionisana azapoliciklična jedinjenja | |
| BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
| MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
| MA28675B1 (fr) | Piperazinediones utilises en tant qu'antagonistes du recepteur de l'oxytocine | |
| SE9903894D0 (sv) | Novel compounds | |
| FR2870541A1 (fr) | Derives de pyrimidines antigonistes du recepteur de la vitronectine | |
| MA29989B1 (fr) | Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie | |
| MXPA05014068A (es) | Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina. | |
| DE60139409D1 (de) | Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen | |
| MA30308B1 (fr) | Dérivés de benzoisoindole utilisés dans le traitement de la douleur | |
| FR2869611A1 (fr) | Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique | |
| TNSN06440A1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
| FR2393577A1 (fr) | Medicament a base d'acide b-(p-halogenophenyl)-g-aminobutyrique destine au traitement de la nevrose d'angoisse |